|
DE19624659A1
(de)
*
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
|
DE19756261A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19756236A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
|
DE19818044A1
(de)
*
|
1998-04-22 |
1999-10-28 |
Klinge Co Chem Pharm Fab |
Verwendung von Vitamin-PP-Verbindungen
|
|
DE69921351T2
(de)
*
|
1998-11-17 |
2006-03-09 |
F. Hoffmann-La Roche Ag |
4-Aroyl-Piperidin-CCR-3 Rezeptorantagonisten III
|
|
EP1031564A1
(en)
*
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
|
US6432432B1
(en)
|
1999-03-05 |
2002-08-13 |
Arch Chemicals, Inc. |
Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
|
|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
CO5370679A1
(es)
|
1999-06-01 |
2004-02-27 |
Smithkline Beecham Corp |
Inhibidores fab 1
|
|
ATE285821T1
(de)
*
|
1999-10-08 |
2005-01-15 |
Affinium Pharm Inc |
Fab i inhibitoren
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
CA2444597A1
(en)
|
2001-04-06 |
2002-10-06 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
FR2823975B1
(fr)
*
|
2001-04-27 |
2003-05-30 |
Sanofi Synthelabo |
Nouvelle utilisation de pyridoindolone
|
|
EP1348434A1
(en)
*
|
2002-03-27 |
2003-10-01 |
Fujisawa Deutschland GmbH |
Use of pyridyl amides as inhibitors of angiogenesis
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
|
US20110045065A1
(en)
*
|
2005-07-11 |
2011-02-24 |
Ashok Vasantray Vyas |
Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
|
|
WO2007053499A2
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
WO2007053498A1
(en)
|
2005-11-01 |
2007-05-10 |
Millennium Pharmaceuticals, Inc. |
Compounds useful as antagonists of ccr2
|
|
EP2687533B1
(en)
|
2006-07-20 |
2017-07-19 |
Debiopharm International SA |
Acrylamide derivatives as FAB I inhibitors
|
|
WO2008026018A1
(en)
|
2006-09-01 |
2008-03-06 |
Topotarget Switzerland Sa |
New method for the treatment of inflammatory diseases
|
|
WO2008098374A1
(en)
|
2007-02-16 |
2008-08-21 |
Affinium Pharmaceuticals, Inc. |
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
EP2098231A1
(en)
|
2008-03-05 |
2009-09-09 |
Topotarget Switzerland SA |
Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
|
|
RU2529468C2
(ru)
|
2008-06-24 |
2014-09-27 |
Топотаргет А/С |
Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида
|
|
JP5688367B2
(ja)
|
2008-08-29 |
2015-03-25 |
トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ |
新規なウレアおよびチオウレア誘導体
|
|
US8426446B2
(en)
|
2009-05-12 |
2013-04-23 |
Beijing Shiqiao Biopharm Co. Ltd. |
Acrylamide derivative and use thereof in manufacture of medicament
|
|
CA2768338A1
(en)
|
2009-07-17 |
2011-01-20 |
Topotarget A/S |
Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
|
|
WO2011121055A1
(en)
|
2010-03-31 |
2011-10-06 |
Topotarget A/S |
Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
|
|
JP6038792B2
(ja)
|
2010-09-03 |
2016-12-07 |
フォーマ ティーエム， エルエルシー． |
癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
|
|
PE20140011A1
(es)
|
2010-09-03 |
2014-01-31 |
Forma Tm Llc |
Compuestos y composiciones novedosos para la inhibicion de nampt
|
|
CN106243023A
(zh)
|
2010-09-03 |
2016-12-21 |
福马Tm有限责任公司 |
用于抑制nampt的胍化合物和组合物
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
KR101916481B1
(ko)
*
|
2010-09-29 |
2018-11-07 |
인터벳 인터내셔널 비.브이. |
Ｎ-헤테로아릴 화합물
|
|
EP2640704A1
(en)
|
2010-11-15 |
2013-09-25 |
Abbvie Inc. |
Nampt inhibitors
|
|
AU2011329233A1
(en)
|
2010-11-15 |
2013-05-23 |
Abbvie Deutschland Gmbh & Co Kg |
NAMPT and ROCK inhibitors
|
|
RU2017112522A
(ru)
*
|
2011-05-04 |
2019-01-24 |
ФОРМА ТиЭм, ЭлЭлСИ |
Новые соединения и композиции для ингибирования nampt
|
|
WO2012154194A1
(en)
|
2011-05-09 |
2012-11-15 |
Forma Tm, Llc |
Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
|
|
SMT201800171T1
(it)
|
2011-07-29 |
2018-07-17 |
Karyopharm Therapeutics Inc |
Modulatori di trasporto nucleare contenenti idrazide e loro usi
|
|
CA2872190C
(en)
|
2012-05-09 |
2024-06-25 |
Karyopharm Therapeutics, Inc. |
Nuclear transport modulators and uses thereof
|
|
US8975398B2
(en)
|
2012-05-11 |
2015-03-10 |
Abbvie Inc. |
NAMPT inhibitors
|
|
CA2873075A1
(en)
|
2012-05-11 |
2013-07-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
MX2014013758A
(es)
|
2012-05-11 |
2015-02-05 |
Abbvie Inc |
Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
|
|
AR091022A1
(es)
|
2012-05-11 |
2014-12-30 |
Abbvie Inc |
Inhibidores del nampt
|
|
SI2861608T1
(sl)
|
2012-06-19 |
2019-08-30 |
Debiopharm International Sa |
Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
|
|
WO2014085607A1
(en)
*
|
2012-11-29 |
2014-06-05 |
Karyopharm Therapeutics Inc. |
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
|
|
US10202366B2
(en)
|
2013-03-15 |
2019-02-12 |
Karyopharm Therapeutics Inc. |
Methods of promoting wound healing using CRM1 inhibitors
|
|
DK3492455T3
(da)
|
2013-06-21 |
2023-08-14 |
Karyopharm Therapeutics Inc |
1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
|
|
EP3016946B1
(en)
*
|
2013-07-03 |
2022-10-12 |
Karyopharm Therapeutics Inc. |
Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof
|
|
WO2015042414A1
(en)
|
2013-09-20 |
2015-03-26 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and methods of using same
|
|
CA2921532A1
(en)
*
|
2013-10-09 |
2015-04-16 |
Eli Lilly And Company |
Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
|
|
AU2015293534A1
(en)
|
2014-07-23 |
2017-02-02 |
Aurigene Discovery Technologies Limited |
4,5-dihydroisoxazole derivatives as NAMPT inhibitors
|
|
CN111484483B
(zh)
|
2014-08-15 |
2023-05-26 |
卡尔约药物治疗公司 |
赛灵克斯的多晶型物
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
CN104447486B
(zh)
*
|
2015-01-13 |
2016-06-01 |
佛山市赛维斯医药科技有限公司 |
二烯氟代金刚烷类化合物、其制备方法和用途
|
|
CN104447483B
(zh)
*
|
2015-01-13 |
2016-07-27 |
佛山市赛维斯医药科技有限公司 |
含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
|
|
CN104447484B
(zh)
*
|
2015-01-13 |
2016-06-08 |
佛山市赛维斯医药科技有限公司 |
含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
HK1255438A1
(zh)
|
2015-08-18 |
2019-08-16 |
卡尔约药物治疗公司 |
用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
|
|
TWI730985B
(zh)
*
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
WO2017117535A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
WO2017117447A1
(en)
|
2015-12-31 |
2017-07-06 |
Karyopharm Therapeutics Inc. |
Multicyclic compounds and uses thereof
|
|
US10526295B2
(en)
|
2015-12-31 |
2020-01-07 |
Karyopharm Therapeutics Inc. |
Nuclear transport modulators and uses thereof
|
|
BR122023021456A2
(pt)
|
2016-02-26 |
2024-02-20 |
Debiopharm International S.A. |
Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
|
|
EP3279192A1
(en)
|
2016-08-05 |
2018-02-07 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Piperidine derivatives for use in the treatment of pancreatic cancer
|
|
WO2018086703A1
(en)
|
2016-11-11 |
2018-05-17 |
Bayer Pharma Aktiengesellschaft |
Dihydropyridazinones substituted with phenylureas
|
|
US11602530B2
(en)
|
2016-11-28 |
2023-03-14 |
Biogen Ma Inc. |
CRM1 inhibitors for treating epilepsy
|
|
CN107827897A
(zh)
*
|
2017-10-23 |
2018-03-23 |
青岛大学 |
一种手性七元螺环吲哚酮类化合物的合成方法
|
|
JP2021512103A
(ja)
|
2018-01-31 |
2021-05-13 |
バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
|
|
KR102831570B1
(ko)
|
2018-05-04 |
2025-07-10 |
레미디 플랜, 인크. |
암 줄기 세포를 표적화하는 암 치료
|
|
CN108558840B
(zh)
*
|
2018-06-04 |
2020-11-06 |
上海交通大学 |
水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
LT3923914T
(lt)
|
2019-02-14 |
2023-07-25 |
Debiopharm International S.A. |
Afabicino kompozicija, jos gamybos būdas
|
|
CN113939306B
(zh)
|
2019-06-14 |
2024-07-19 |
德彪药业国际股份公司 |
用于治疗涉及生物膜的细菌感染的药物及其用途
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
AU2020378067A1
(en)
|
2019-11-06 |
2022-05-26 |
Remedy Plan, Inc. |
Cancer treatments targeting cancer stem cells
|
|
JP2024518089A
(ja)
|
2021-05-13 |
2024-04-24 |
リメディー プラン，インコーポレーテッド |
Ｎａｍｐｔ阻害剤とその使用
|